A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis

Injection site reactions (ISRs) are a common side effect of subcutaneous interferon beta therapy, particularly during initiation of therapy. Retrospective analysis of two clinical trials showed that patients using an autoinjector experienced fewer ISRs than patients administering interferon beta man...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2005-10, Vol.11 (5), p.585-591
Main Authors: Mikol, D, Lopez-Bresnahan, M, Taraskiewicz, S, Chang, P, Rangnow, J
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Adjuvants, Immunologic - adverse effects
Adolescent
Adult
Aged
Female
Humans
Injections, Subcutaneous - adverse effects
Injections, Subcutaneous - methods
Interferon beta-1a
Interferon-beta - administration & dosage
Interferon-beta - adverse effects
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Neurologic Examination
Patient Compliance
Self Administration
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Injection site reactions (ISRs) are a common side effect of subcutaneous interferon beta therapy, particularly during initiation of therapy. Retrospective analysis of two clinical trials showed that patients using an autoinjector experienced fewer ISRs than patients administering interferon beta manually. This randomized, open-label trial compared the occurrence of ISRs in relapsing-remitting multiple sclerosis patients subcutaneously injecting interferon beta-1a manually or with autoinjector. In total, 1825 patients (autoinjector, 932; manual injection, 893) were included in the intention-to-treat analysis. Significantly fewer patients using the autoinjector experienced ISRs, based on physician assessment, compared with manual injection (78.7% versus 85.4%; p
ISSN:1352-4585
1477-0970
DOI:10.1191/1352458505ms1197oa